News Sarepta DMD gene therapy could improve patients' motor funct... Sarepta Therapeutics announced potentially game-changing results from its Duchenne muscular dystrophy gene therapy candidate, with a small phase 1 trial showing an improvement in patients’
DMD Main Curing DMD: Travelling together to find a meaningful destina... For many years, Duchenne muscular dystrophy (DMD) was something of a forgotten disease.
Disease Spotlight Increase collaboration to widen access to DMD drugs, trials ... When it comes to fighting a rare disease like Duchenne muscular dystrophy (DMD), it’s a matter of strength in numbers.
News Pfizer axes development of Duchenne muscular dystrophy antib... Pfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy targets.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
